{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:04:57Z","timestamp":1772168697395,"version":"3.50.1"},"reference-count":51,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chem. Pharm. Bull.","CHEMICAL &amp; PHARMACEUTICAL BULLETIN"],"published-print":{"date-parts":[[2025,8,9]]},"DOI":"10.1248\/cpb.c25-00198","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T22:07:46Z","timestamp":1754690866000},"page":"670-677","source":"Crossref","is-referenced-by-count":0,"title":["Novel Approach to Pre-Exposure Prophylaxis (PrEP) of COVID-19: Development of S-892216 Long-Acting Injectable Suspension"],"prefix":"10.1248","volume":"73","author":[{"given":"Ryo","family":"Ohashi","sequence":"first","affiliation":[{"name":"Formulation R&amp;D Laboratory, Pharmaceutical Technology Research Division, Shionogi &amp; Co., Ltd., 2\u20131\u20133 Kuise Terajima, Amagasaki, Hyogo 660\u20130813, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Watari","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Development, Shionogi &amp; Co., Ltd., 3\u20131\u20131 Futaba-cho, Toyonaka, Osaka 561\u20130825, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kondo","sequence":"additional","affiliation":[{"name":"Formulation R&amp;D Laboratory, Pharmaceutical Technology Research Division, Shionogi &amp; Co., Ltd., 2\u20131\u20133 Kuise Terajima, Amagasaki, Hyogo 660\u20130813, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Otake","sequence":"additional","affiliation":[{"name":"Formulation R&amp;D Laboratory, Pharmaceutical Technology Research Division, Shionogi &amp; Co., Ltd., 2\u20131\u20133 Kuise Terajima, Amagasaki, Hyogo 660\u20130813, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Murata","sequence":"additional","affiliation":[{"name":"Formulation R&amp;D Laboratory, Pharmaceutical Technology Research Division, Shionogi &amp; Co., Ltd., 2\u20131\u20133 Kuise Terajima, Amagasaki, Hyogo 660\u20130813, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Kimura","sequence":"additional","affiliation":[{"name":"Formulation R&amp;D Laboratory, Pharmaceutical Technology Research Division, Shionogi &amp; Co., Ltd., 2\u20131\u20133 Kuise Terajima, Amagasaki, Hyogo 660\u20130813, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) World Health Organization, \u201cTimeline: WHO\u2019s response to COVID-19.\u201d: &lt;https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/interactive-timeline&gt;, cited 2 December, 2024."},{"key":"2","unstructured":"2) World Health Organization, \u201cStatement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic.\u201d: &lt;https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic#:~:text=The%20WHO%20Director%2DGeneral%20concurs,of%20international%20concern%20(PHEIC)&gt;, cited 2 December, 2024."},{"key":"3","unstructured":"3) World Health Organization, \u201cCOVID-19 deaths WHO COVID-19 dashboard.\u201d: &lt;https:\/\/data.who.int\/dashboards\/covid19\/deaths&gt;, cited 2 December, 2024."},{"key":"4","unstructured":"4) Ministry of Health, Labour and Welfare, \u201cResponse to COVID 19 (Novel Coronavirus) after the classification change.\u201d: &lt;https:\/\/www.mhlw.go.jp\/stf\/covid-19\/kenkou-iryousoudan_00006.html&gt;, cited 2 December 2024."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Chavda V. P., Ghali E.N.H. K., Balar P. C., Chauhan S. C., Tiwari N., Shukla S., Athalye M., Patravale V., Apostolopoulos V., Yallapu M. M., <i>J. Control. Release<\/i>, <b>366<\/b>, 761\u2013782 (2024).","DOI":"10.1016\/j.jconrel.2024.01.017"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Iwata S., Pollard A. J., Tada Y., Omoto S., Shibata R. Y., Igarashi K., Hasegawa T., Ariyasu M., Sonoyama T., <i>Sci. Rep<\/i>., <b>14<\/b>, 9830 (2024).","DOI":"10.1038\/s41598-024-57308-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Zhang J. J., Dong X., Liu G. H., Gao Y. D., <i>Clin. Rev. Allergy Immunol<\/i>., <b>64<\/b>, 90\u2013107 (2023).","DOI":"10.1007\/s12016-022-08921-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Chi W. Y., Li Y. D., Huang H. C., Chan T.E. H., Chow S. Y., Su J. H., Ferrall L., Hung C. F., Wu T. C., <i>J. Biomed. Sci.<\/i>, <b>29<\/b>, 82 (2022).","DOI":"10.1186\/s12929-022-00853-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) He X., Su J., Ma Y., Zhang W., Tang S., <i>Front. Immunol.<\/i>, <b>13<\/b>, 945930 (2022).","DOI":"10.3389\/fimmu.2022.945930"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ouyang J., Zaongo S. D., Harypursat V., Li X., Routy J. P., Chen Y., <i>Front.Public Health<\/i>, <b>10<\/b>, 945448 (2022).","DOI":"10.3389\/fpubh.2022.945448"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kang S. W., Kim J. W., Kim J. Y., Lim S. Y., Jang C. Y., Chang E., Yang J. S., Kim K. C., Jang H. C., Kim D., Shin Y., Lee J. Y., Kim S. H., <i>J. Infect.<\/i>, <b>86<\/b>, 412\u2013414 (2023).","DOI":"10.1016\/j.jinf.2023.01.024"},{"key":"12","unstructured":"12) World Health Organization, \u201cInterim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons.\u201d: &lt;https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-immunocompromised-persons&gt;, cited 2 December, 2024."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Levin M. J., Ustianowski A., De Wit S., <i>et al<\/i>., <i>N. Engl. J. Med.<\/i>, <b>386<\/b>, 2188\u20132200 (2022).","DOI":"10.1056\/NEJMoa2116620"},{"key":"14","unstructured":"14) Food and Drug Administration, \u201cFDA announces Evusheld is not currently authorized for emergency use in the U.S.\u201d: &lt;https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us&gt;, cited 2 December, 2024."},{"key":"15","unstructured":"15) Cai Y., Diallo S., Rosenthal K., <i>et al<\/i>., Sci. <i>Transl. Med.<\/i>, <b>16<\/b>, eado2817 (2024)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Owen A., Rannard S., <i>Adv. Drug Deliv. Rev.<\/i>, <b>103<\/b>, 144\u2013156 (2016).","DOI":"10.1016\/j.addr.2016.02.003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Remenar J. F., <i>Mol. Pharm<\/i>., <b>11<\/b>, 1739\u20131749 (2014).","DOI":"10.1021\/mp500070m"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Holm R., Lee R. W., Glassco J., DiFranco N., Bao Q., Burgess D. J., Lukacova V., Alidori S., <i>AAPS J.<\/i>, <b>25<\/b>, 49 (2023).","DOI":"10.1208\/s12248-023-00811-8"},{"key":"19","unstructured":"19) Unoh Y., Hirai K., Uehara S., <i>et al<\/i>., <i>bioRxiv,<\/i> 2025-02 (2025)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Shi J., Wang D., Tian Y., Wang Z., Gao J., Liu N., Gao X., Zheng A., Zhang H., Xiang M., <i>Pharmaceutics<\/i>, <b>14<\/b>, 1094 (2022).","DOI":"10.3390\/pharmaceutics14051094"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ho M. J., Jeong M. Y., Jeong H. T., Kim M. S., Park H. J., Kim D. Y., Lee H. C., Song W. H., Kim C. H., Lee C. H., Choi Y. W., Choi Y. S., Han Y. T., Kang M. J., <i>J. Control. Release<\/i>, <b>341<\/b>, 533\u2013547 (2022).","DOI":"10.1016\/j.jconrel.2021.12.011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Baert L., van\u2019t Klooster G., Dries W., Fran\u00e7ois M., Wouters A., Basstanie E., Iterbeke K., Stappers F., Stevens P., Schueller L., Van Remoortere P., Kraus G., Wigerinck P., Rosier J., <i>Eur. J. Pharm. Biopharm.<\/i>, <b>72<\/b>, 502\u2013508 (2009).","DOI":"10.1016\/j.ejpb.2009.03.006"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) van\u2019t Klooster G., Hoeben E., Borghys H., Looszova A., Bouche M. P., van Velsen F., Baert L., <i>Antimicrob . Agents Chemother.<\/i>, <b>54<\/b>, 2042\u20132050 (2010).","DOI":"10.1128\/AAC.01529-09"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Leng D., Chen H., Li G., Guo M., Zhu Z., Xu L., Wang Y., <i>Int. J. Pharm.<\/i>, <b>472<\/b>, 380\u2013385 (2014).","DOI":"10.1016\/j.ijpharm.2014.05.052"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Nakach M., Authelin J. R., Perrin M. A., Lakkireddy H. R., <i>Int. J. Pharm.<\/i>, <b>547<\/b>, 61\u201371 (2018).","DOI":"10.1016\/j.ijpharm.2018.05.042"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Tanaka H., Ochii Y., Moroto Y., Ibaraki T., Ogawara K. I., <i>Chem. Pharm. Bull.<\/i>, <b>69<\/b>, 81\u201385 (2021).","DOI":"10.1248\/cpb.c20-00623"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Limwikrant W., Aung T., Chooluck K., Puttipipatkhachorn S., Yamamoto K., <i>Chem. Pharm. Bull.<\/i>, <b>67<\/b>, 389\u2013392 (2019).","DOI":"10.1248\/cpb.c18-00589"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Jucker B. M., Alsaid H., Rambo M., Lenhard S. C., Hoang B., Xie F., Groseclose M. R., Castellino S., Damian V., Bowers G., Gupta M., <i>J. Control. Release<\/i>, <b>268<\/b>, 102\u2013112 (2017).","DOI":"10.1016\/j.jconrel.2017.10.017"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Lestari M. L., M\u00fcller R. H., M\u00f6schwitzer J. P., <i>J. Pharm. Sci.<\/i>, <b>104<\/b>, 1128\u20131140 (2015).","DOI":"10.1002\/jps.24266"},{"key":"30","unstructured":"30) European Medicines Agency, \u201cAssessment report Vocabria Procedure No. EMEA\/H\/C\/004976\/0000.\u201d: &lt;https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vocabria#assessment-history&gt;, cited 2 December, 2024."},{"key":"31","unstructured":"31) European Medicines Agency, \u201cAssessment report Rekambys Procedure No. EMEA\/H\/C\/005060\/0000.\u201d: &lt;https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rekambys&gt;, cited 2 December, 2024."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Bollenbach L., Buske J., M\u00e4der K., Garidel P., <i>Int. J. Pharm.<\/i>, <b>620<\/b>, 121706 (2022).","DOI":"10.1016\/j.ijpharm.2022.121706"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Verma S., Gokhale R., Burgess D. J., <i>Int. J. Pharm.<\/i>, <b>380<\/b>, 216\u2013222 (2009).","DOI":"10.1016\/j.ijpharm.2009.07.005"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Tanaka Y., Inkyo M., Yumoto R., Nagai J., Takano M., Nagata S., <i>Chem. Pharm. Bull.<\/i>, <b>57<\/b>, 1050\u20131057 (2009).","DOI":"10.1248\/cpb.57.1050"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Liu P., Rong X., Laru J., van Veen B., Kiesvaara J., Hirvonen J., Laaksonen T., Peltonen L., <i>Int. J. Pharm.<\/i>, <b>411<\/b>, 215\u2013222 (2011).","DOI":"10.1016\/j.ijpharm.2011.03.050"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Zulbeari N., Hansen M., Morgen P., Holm R., <i>J. Drug Deliv. Sci. Technol.<\/i>, <b>95<\/b>, 105605 (2024).","DOI":"10.1016\/j.jddst.2024.105605"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Elmowafy M., Shalaby K., Al-Sanea M. M., Hendawy O. M., Salama A., Ibrahim M. F., Ghoneim M. M., <i>Pharmaceutics<\/i>, <b>13<\/b>, 1812 (2021).","DOI":"10.3390\/pharmaceutics13111812"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Singare D. S., Marella S., Gowthamrajan K., Kulkarni G. T., Vooturi R., Rao P. S., <i>Int. J. Pharm.<\/i>, <b>402<\/b>, 213\u2013220 (2010).","DOI":"10.1016\/j.ijpharm.2010.09.041"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Chamanza R., Darville N., van Heerden M., De Jonghe S., <i>Toxicol. Pathol.<\/i>, <b>46<\/b>, 85\u2013100 (2018).","DOI":"10.1177\/0192623317737295"},{"key":"40","unstructured":"40) Oncology Nurse Advisor, \u201cLarge-volume IM injections: A review of best practices.\u201d: &lt;https:\/\/www.oncologynurseadvisor.com\/features\/large-volume-im-injections-a-review-of-best-practices\/&gt;, cited 2 December, 2024."},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Mathaes R., Koulov A., Joerg S., Mahler H. C., <i>J. Pharm. Sci.<\/i>, <b>105<\/b>, 2255\u20132259 (2016).","DOI":"10.1016\/j.xphs.2016.05.029"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Medlicott N. J., Waldron N. A., Foster T. P., <i>Adv. Drug Deliv. Rev.<\/i>, <b>56<\/b>, 1345\u20131365 (2004).","DOI":"10.1016\/j.addr.2004.02.005"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Johnson A. R., Ballard J. E., Leithead A., Miller C., Faassen F., Zang X., Nofsinger R., Wagner A. M., <i>Pharm. Res.<\/i>, <b>40<\/b>, 1641\u20131656 (2023).","DOI":"10.1007\/s11095-023-03470-8"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Nguyen V.T. T., Darville N., Vermeulen A., <i>AAPS J.<\/i>, <b>25<\/b>, 4 (2022).","DOI":"10.1208\/s12248-022-00771-5"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Hirano K., Ichihashi T., Yamada H., <i>Chem. Pharm. Bull.<\/i>, <b>29<\/b>, 817\u2013827 (1981).","DOI":"10.1248\/cpb.29.817"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Hirano K., Yamada H., <i>J. Pharm. Sci.<\/i>, <b>71<\/b>, 500\u2013505 (1982).","DOI":"10.1002\/jps.2600710506"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Groseclose M. R., Castellino S., <i>Int. J. Mass Spectrom.<\/i>, <b>437<\/b>, 92\u201398 (2019).","DOI":"10.1016\/j.ijms.2018.05.006"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Darville N., Van Heerden M., Vynckier A., De Meulder M., Sterkens P., Annaert P., Van den Mooter G., <i>J. Pharm. Sci.<\/i>, <b>103<\/b>, 2072\u20132087 (2014).","DOI":"10.1002\/jps.24014"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Bauer A., Berben P., Chakravarthi S. S., <i>et al<\/i>., <i>Pharm. Res.<\/i>, <b>40<\/b>, 1601\u20131631 (2023).","DOI":"10.1007\/s11095-022-03391-y"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Kerwin B. A., <i>J. Pharm. Sci.<\/i>, <b>97<\/b>, 2924\u20132935 (2008).","DOI":"10.1002\/jps.21190"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Kishore R. S., Pappenberger A., Dauphin I. B., Ross A., Buergi B., Staempfli A., Mahler H. C., <i>J. Pharm. Sci.<\/i>, <b>100<\/b>, 721\u2013731 (2011).","DOI":"10.1002\/jps.22290"}],"container-title":["Chemical and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpb\/73\/8\/73_c25-00198\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T03:52:46Z","timestamp":1754711566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpb\/73\/8\/73_c25-00198\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/cpb.c25-00198","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2025-2q127","asserted-by":"object"}]},"ISSN":["0009-2363","1347-5223"],"issn-type":[{"value":"0009-2363","type":"print"},{"value":"1347-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"article-number":"c25-00198"}}